Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics has signed two new strategic development agreements with Pari Pharma.
Subscribe to our email newsletter
One of these agreements is for the conjoint clinical development of aerosolized AAT for treating the indications of cystic fibrosis and bronchiectasis, in addition to Alpha-1 Antitrypsin Deficiency (AATD). Under the agreement Pari grants Kamada an exclusive license to use an optimized eFlow Electronic Nebulizer to deliver AAT in its clinical trials also for these indications. The other agreement is a long term agreement to supply the optimized eFlow for the marketing, distribution, and commercialization of Kamada’s AAT, pending successful conclusion of the clinical trials.
David Tsur, CEO of Kamada, said: “The next generation product, AAT for inhalation, holds numerous advantages over the currently used AAT for intravenous administration. Among these advantages are greater patient convenience, reduced treatment costs, larger treatment population and additional potential indications, all pending successful completion of the company’s clinical development plan.”